Organ-on-a-chip

Deerfield Management Announces XSeed Award Winners

Retrieved on: 
Tuesday, March 8, 2022
Professional Services, Philanthropy, Health, Surgery, Finance, Foundation, General Health, Heart, Government, Lists of video games, Industry, Laboratory, Memorial Sloan Kettering Cancer Center, Organ-on-a-chip, Research, Partnership, Therapy, Cancer, Neurodegeneration, Albert Einstein College of Medicine, Dementia, MD, Lists of diseases, Economic development, Neuron, Woman, Mentorship, Atrophy, Company, Patient, Program, Council, Technology, Lecture, Health care, Park Avenue, Drug discovery, List of life sciences, New Yorkers, Lipid metabolism, CEO, Wellington Management Company, NYCEDC, Pharmaceutical industry, Public relations, Medicine, Cure, Biochemistry, the XSeed Award, Deerfield Management, Cure, the XSeed Award, Deerfield Management, Cure, THE XSEED AWARD, DEERFIELD MANAGEMENT, Cure

Deerfield Management Company today announces the grant recipients of its second annual XSeed Award .

Key Points: 
  • Deerfield Management Company today announces the grant recipients of its second annual XSeed Award .
  • This year each of the five New York City-based award winners receives a $100,000 grant to further projects focused on neurodegeneration.
  • We are proud XSeed was borne out of our redevelopment of the Cure with Deerfield Management in 2019.
  • The XSeed Award is a result of the launch of Cure , a 12-story innovation hub in Manhattan redeveloped in partnership with Deerfield Management and New York City Economic Development Corporation (NYCEDC).

Asia Pacific Organoids Market Forecast to 2027: Amalgamation of Organ-on-Chip with Organoids to be a Prevalent Trend - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021
Health, Biotechnology, Tissue engineering, Stem cells, Biology, Life sciences, Organoid, Technology, Organ-on-a-chip, Cerebral organoid

b'The "Asia Pacific Organoids Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Application; Source, and Country" report has been added to ResearchAndMarkets.com\'s offering.\n\'Asia-Pacific Organoids Market is expected to reach US$ 513.74 Mn in 2027 from US$ 97.02 Mn in 2019.

Key Points: 
  • b'The "Asia Pacific Organoids Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Application; Source, and Country" report has been added to ResearchAndMarkets.com\'s offering.\n\'Asia-Pacific Organoids Market is expected to reach US$ 513.74 Mn in 2027 from US$ 97.02 Mn in 2019.
  • The market is estimated to grow with a CAGR of 23.1% from 2020-2027.\nOrganoid and organ-on-a-chip, which are served as evolving pathological and human physiological relevant in vitro models, hold an excessive potential to revolutionize the conventional example in basic and clinical research.\nThe recent inclination in the collaborative application of organoid with organ-on-a-chip and 3D bio printing enables development of sophisticated cancer models to study underlying mechanisms of tumour-stroma interactions, multi-organ tumour metastasis, and cancer-microenvironment interactions.\nBy incorporating multiple organoids into organ-on-a-chip, organoid-on-a-chip can inherit both organoid and organ-on-a-chip benefits and provides a useful tool to study multi-organ tumour metastases and cancer-microenvironment interactions.
  • Overall, researchers expect that these emerging in vitro cancer model systems will ultimately revolutionize the conventional paradigm of cancer research and produce real clinical benefits.\nKey driving factor such as rising adoption of bio-banking and tumour modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the market.
  • However, lack of expertise is likely to have a negative impact on the growth of the market in the coming years.\n'

Harnessing Human Tissue Models for Drug Development - New Research from Draper

Retrieved on: 
Tuesday, April 13, 2021
Biotechnology, Nanotechnology, Microfluidics, Technology, Science and technology, Materials science, Tissue engineering, Organ-on-a-chip, MIMETAS

Now, a series of proof of concept experiments led by Draper and Pfizer has demonstrated progress toward that standard.

Key Points: 
  • Now, a series of proof of concept experiments led by Draper and Pfizer has demonstrated progress toward that standard.
  • "Here we present an OOC platform preserving those functional considerations yet with advanced culture capabilities supporting a variety of human tissue models including liver, vascular, gastrointestinal and kidney.
  • "\nThe team seeded, grew and tested the human tissue models in Draper\'s PREDICT96 high-throughput microfluidic testing platform .
  • Unlike most microfluidic testing platforms that have fewer than a dozen replicates, Draper\'s platform can hold 96 individual organ tissue models in one microfluidic culture plate.

CN Bio introduces the PhysioMimix™ OOC Multi-Organ Microphysiological System

Retrieved on: 
Wednesday, March 17, 2021
Biotechnology, Health, Clinical trials, Medical devices, Tissue engineering, Biotechnology, Microfluidics, Nanotechnology, Organ-on-a-chip, Alternatives to animal testing, OOC, Science and technology, In vitro, Life sciences, Biology

CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS.

Key Points: 
  • CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS.
  • CN Bios Multi-Organ MPS enables researchers to generate sophisticated in vitro models that better represent human inter-organ crosstalk effects compared to single-organ MPS, or animal models.
  • Prior to launch, the system has undergone extensive internal and external validation by the University of Pittsburgh, and by a major pharmaceutical company.
  • For future details on the PhysioMimix OOC range, now comprising the PhysioMimix Single-Organ and PhysioMimix Multi-Organ Systems, please visit: https://cn-bio.com/physiomimixooc/
    For a high-resolution image please contact Zyme Communications.

AIM Biotech Launches Organ-on-a-Chip Contract Research Service

Retrieved on: 
Tuesday, March 2, 2021
Drug discovery, Health sciences, Pharmaceutical industry, Life sciences, Health, Preclinical development, Organ-on-a-chip, Clinical trial

Singapore & Boston, Massachusetts--(Newsfile Corp. - March 2, 2021) - AIM Biotech has launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development.

Key Points: 
  • Singapore & Boston, Massachusetts--(Newsfile Corp. - March 2, 2021) - AIM Biotech has launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development.
  • As a result, drug discovery organizations can generate more predictive data and better inform their decisions ahead of clinical trials.
  • AIM gives researchers 3D human biology-on-a-chip to revolutionize their preclinical drug discovery and molecular research.
  • AIM Biotech is located in Singapore and Boston, MA.

AIM Biotech to Present at Biotech Showcase(TM) 2021; To Highlight Expansion of its Organ-on-a-Chip Business

Retrieved on: 
Monday, January 11, 2021
McGorry, Organ-on-a-chip, Science and technology, Technology, Natural sciences

AIM Biotech is participating in Biotech Showcase 2021, where CEO Jim McGorry will share the Company's plan to commercialize its organ-on-a-chip product line and contract research services.

Key Points: 
  • AIM Biotech is participating in Biotech Showcase 2021, where CEO Jim McGorry will share the Company's plan to commercialize its organ-on-a-chip product line and contract research services.
  • Registered attendees may access recorded company presentations prior to the event, schedule direct meetings and engage in Q&A with management.
  • CEO Jim McGorry will share the company's plan to expand its organ-on-a-chip business.
  • AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development.

Organ-On-Chip (OOC) Market Size is USD 303.6 Million by 2026 at CAGR 39.9% | Valuates Reports

Retrieved on: 
Monday, January 11, 2021
Science and technology, Technology, Microfluidics, Nanotechnology, Biotechnology, Organ-on-a-chip, Tissue engineering, Materials science, Clonal hematopoiesis, Integrated circuit

The global Organ-on-a-Chip Market size is projected to reach USD 303.6 Million by 2026, from USD 41 Million in 2020, at a CAGR of 39.9% during 2021-2026.

Key Points: 
  • The global Organ-on-a-Chip Market size is projected to reach USD 303.6 Million by 2026, from USD 41 Million in 2020, at a CAGR of 39.9% during 2021-2026.
  • This feature is expected to drive the growth of organs on the chip market size.
  • The increasing instances of Cardiovascular diseases (CVD) are expected to drive the growth of organ-on-a-chip market size.
  • Furthermore, the substantial increase in demand for early detection of drug toxicity is expected to fuel the organ-on-chip market size.

Organ-On-Chip (OOC) Market Size is USD 303.6 Million by 2026 at CAGR 39.9% | Valuates Reports

Retrieved on: 
Monday, January 11, 2021
Science and technology, Technology, Microfluidics, Nanotechnology, Biotechnology, Organ-on-a-chip, Tissue engineering, Materials science, Clonal hematopoiesis, Integrated circuit

The global Organ-on-a-Chip Market size is projected to reach USD 303.6 Million by 2026, from USD 41 Million in 2020, at a CAGR of 39.9% during 2021-2026.

Key Points: 
  • The global Organ-on-a-Chip Market size is projected to reach USD 303.6 Million by 2026, from USD 41 Million in 2020, at a CAGR of 39.9% during 2021-2026.
  • This feature is expected to drive the growth of organs on the chip market size.
  • The increasing instances of Cardiovascular diseases (CVD) are expected to drive the growth of organ-on-a-chip market size.
  • Furthermore, the substantial increase in demand for early detection of drug toxicity is expected to fuel the organ-on-chip market size.

Fluxion Launches BioFlux One, the Affordable System for Cellular Interaction Assays Under Physiological Flow

Retrieved on: 
Wednesday, March 18, 2020
Natural sciences, Branches of biology, Articles, Microfluidics, Biotechnology, Nanotechnology, Laboratory techniques, Assay, Organ-on-a-chip, Cell sorting

The BioFlux One system is the solution for labs that run flow cell experiments but don't need 2-phase flow.

Key Points: 
  • The BioFlux One system is the solution for labs that run flow cell experiments but don't need 2-phase flow.
  • It provides all the benefits of the industry standard BioFlux system, but at a price point similar to a "home brew" flow cell setup.
  • The BioFlux system is the established standard for a wide range of cellular interaction assays under physiological flow.
  • The heart of the BioFlux One system is identical to the BioFlux 200 and the BioFlux 1000z systems: automated control of flow cell experiments with Fluxions unique microfluidic flow cell well plates.

Company Profile for zPREDICTA, Inc.

Retrieved on: 
Thursday, February 27, 2020
Oncology, Health, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Biology, Branches of biology, Life sciences, Alternatives to animal testing, 3D cell culture, Bioreactors, Cell culture, In vitro, Biotechnology, Organ-on-a-chip, Donald E. Ingber

zPREDICTA is the leading provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics.

Key Points: 
  • zPREDICTA is the leading provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics.
  • Our 3D cell culture models are tissue-specific and disease-specific thus offering higher predictive and analytical value than traditional 2D testing or non-specific 3D models.
  • We provide in vitro testing services to some of the leading global biotechnology and pharmaceutical companies.